A Northwestern Medicine study has offered new clues as to why immunotherapy works well for some bladder cancer patients but ...
Tecentriq combined with BCG did not enhance outcomes for high-risk NMIBC patients compared to BCG alone, with similar event-free survival rates. The ALBAN trial reported higher rates of side effects ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...
Patients with early-stage bladder cancer are often able to maintain their usual routines. Some may experience urinary ...
Credit: Johnson & Johnson. Inlexzo is supplied as a single-dose intravesical system containing 225mg of gemcitabine plus a sterile urinary catheter and stylet. Inlexzo is an intravesical gemcitabine ...
POTOMAC trial patient-reported outcomes support durvalumab plus BCG for BCG-naive, high-risk non-muscle invasive bladder cancer (NMIBC).
Please provide your email address to receive an email when new articles are posted on . Patients with high-risk non-muscle-invasive bladder cancer who received durvalumab plus BCG had improved DFS.
A new survey undertaken by the Harris Poll for Johnson & Johnson has shown how standard forms of surgery and treatment for certain bladder cancer patients are causing a major long-term emotional ...
Inlexzo is an intravesical gemcitabine releasing system that is inserted directly into the bladder through a urinary catheter. The Food and Drug Administration (FDA) has approved Inlexzo ™ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results